{"id":"doi:10.1056/nejmoa1609581","kind":"article","title":"Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease","authors":["Abraham Michael Lincoff","Stephen James Nicholls","Jeffrey Riesmeyer","Philip J. Barter","H Bryan Brewer","Keith A.A. Fox","Charles Michael Gibson","Christopher Bull Granger","Venu Menon","Gilles Montalescot","Daniel James Rader","Alan R. Tall","Ellen Strauss McErlean","Kathy Wolski","Giacomo Ruotolo","Burkhard Vangerow","Govinda J. Weerakkody","Shaun G. Goodman","Diego Conde","Darren K. McGuire","José Carlos Nicolau","Jose Luis Leiva-Pons","Yves Pesant","Weimin Li","David Kandath"],"author_count":29,"year":2017,"published":"2017-05-17","venue":"New England Journal of Medicine","cited_by":801,"doi":"10.1056/nejmoa1609581","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa1609581","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa1609581","updated":null,"pmid":"28514624","pmcid":null,"openalex_id":"W2616536890","pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581?articleTools=true","abstract":null,"abstract_license":null,"license":null,"is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Lipoproteins and Cardiovascular Health"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}